|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Cash Flows from Operating Activities | |||||
| Net loss | |||||
| Adjustments to reconcile net loss to net cash and cash equivalents used in operating activities: | |||||
| Depreciation and amortization | |||||
| Amortization of right-of-use assets | |||||
| Loss on sales of property, plant, and equipment | |||||
| Gain on sales of property, plant, and equipment | |||||
| Loss on extinguishment of note receivable | |||||
| Share of net loss (income) of equity method investee | |||||
| Stock-based compensation expense | |||||
| Change in fair value of warrant liabilities | |||||
| Accretion of discounts on other long-term liabilities | |||||
| Accretion of loan receivable from equity method investee | |||||
| Amortization of premiums and accretion of discounts on available-for-sale securities | |||||
| Loss on change in assessment of finance lease purchase options | |||||
| Impairment loss on abandoned patents | |||||
| Change in operating assets and liabilities that provided (used) cash and cash equivalents: | |||||
| Accounts receivable | |||||
| Contract assets | |||||
| Contract receivables from related parties | |||||
| Prepaid expenses and other current assets and other assets | |||||
| Accounts payable and other accrued liabilities | |||||
| Deferred revenue | |||||
| Deferred revenue from related parties | |||||
| Accrued compensation | |||||
| Operating lease liabilities | |||||
| Net cash and cash equivalents used in operating activities | |||||
| Cash Flows from Investing Activities | |||||
| Purchases of property, plant and equipment | |||||
| Purchases of available-for-sale securities | |||||
| Proceeds from sales of available-for-sale securities | |||||
| Proceeds from sales of property, plant and equipment | |||||
| Cash paid for loan receivable from equity method investee | |||||
| Cash paid for equity method investment | |||||
| Purchases of intangible assets | |||||
| Net cash and cash equivalents provided by (used in) investing activities | |||||
| Cash Flows from Financing Activities | |||||
| Payments of debt | |||||
| Proceeds from exercise of stock options | |||||
| Proceeds from issuance of shares of common stock under the ESPP | |||||
| Cash paid for withholding of employee taxes related to stock-based compensation | |||||
| Payments on finance lease liability | |||||
| Repurchase of shares of common stock | |||||
| Proceeds from the ATM, net of commissions | |||||
| Offering costs for the issuance of common stock under the ATM | |||||
| Payments on finance lease liabilities | |||||
| Net cash and cash equivalents provided by (used in) financing activities | |||||
| Net decrease in cash and cash equivalents | |||||
| Cash and cash equivalents at beginning of period | |||||
| Cash and cash equivalents at end of period | |||||
| Supplemental information | |||||
| Cash paid for interest | |||||
| Accrued capital expenditures | |||||
| Unpaid reimbursement on capital expenditures | |||||
| Accrued offering costs for the issuance of common stock under the ATM | |||||
| Accrued excise tax on stock repurchases | |||||
Loading...